164 related articles for article (PubMed ID: 6245710)
61. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.
Mushlin P; Boerth RC; Wells JN
Mol Pharmacol; 1981 Jul; 20(1):179-89. PubMed ID: 6270531
[No Abstract] [Full Text] [Related]
62. Activation of human lymphocyte high affinity cyclic AMP phosphodiesterase by culture with 1-methyl-3-isobutylxanthine.
Thompson WJ; Ross CP; Hersh EM; Epstein PM; Strada SJ
J Cyclic Nucleotide Res; 1980; 6(1):25-36. PubMed ID: 6155390
[TBL] [Abstract][Full Text] [Related]
63. The effects of alkylated xanthines on cyclic AMP accumulation in dog thyroid slices exposed to carbamylcholine.
Miot F; Erneux C; Wells JN; Dumont JE
Mol Pharmacol; 1984 Mar; 25(2):261-6. PubMed ID: 6321949
[TBL] [Abstract][Full Text] [Related]
64. Cyclic GMP binding and phosphodiesterase: implication for platelet function.
Hamet P; Coquil JF; Bousseau-Lafortune S; Franks DJ; Tremblay J
Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():119-36. PubMed ID: 6202123
[No Abstract] [Full Text] [Related]
65. Influence of polyunsaturated fatty acids on lipid metabolism in human blood mononuclear cells and early biochemical events associated with lymphocyte activation.
Joulain C; Guichardant M; Lagarde M; Prigent AF
J Lipid Mediat Cell Signal; 1995 Jan; 11(1):63-79. PubMed ID: 7728418
[TBL] [Abstract][Full Text] [Related]
66. Modulation of cyclic AMP metabolism by S-adenosylhomocysteine and S-3-deazaadenosylhomocysteine in mouse lymphocytes.
Zimmerman TP; Schmitges CJ; Wolberg G; Deeprose RD; Duncan GS; Cuatrecasas P; Elion GB
Proc Natl Acad Sci U S A; 1980 Oct; 77(10):5639-43. PubMed ID: 6255458
[TBL] [Abstract][Full Text] [Related]
67. Selective inhibition of separated forms of cyclic nucleotide phosphodiesterase from rat heart by some pentasubstituted quercetin analogs.
Picq M; Prigent AF; Nemoz G; Pacheco H
Biochem Pharmacol; 1982 Sep; 31(17):2777-82. PubMed ID: 6291544
[TBL] [Abstract][Full Text] [Related]
68. Cyclic AMP metabolism in peripheral blood lymphocytes from patients with Hodgkin's disease.
Akolkar PN; Advani SH; Gothoskar BP
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1389-92. PubMed ID: 6094195
[TBL] [Abstract][Full Text] [Related]
69. [Properties of cyclic nucleotide phosphodiesterase from lingual taste papillae].
Ostretsova IB
Biokhimiia; 1978 Jun; 43(6):1037-44. PubMed ID: 27246
[TBL] [Abstract][Full Text] [Related]
70. [The seasonal rhythm of changes in adenosine cyclic monophosphate phosphodiesterase activity in the lymphocytes of human peripheral blood].
Kochetkova MN; Ozeretskovskaia NN; Ezhkova NG
Izv Akad Nauk SSSR Biol; 1988; (5):782-5. PubMed ID: 2849615
[No Abstract] [Full Text] [Related]
71. 1-(4-Aminobenzyl)-and 1-(4-aminophenyl)isoquinoline derivatives: synthesis and evaluation as potential irreversible cyclic nucleotide phosphodiesterase inhibitors.
Walker KA; Boots MR; Stubbins JF; Rogers ME; Davis CW
J Med Chem; 1983 Feb; 26(2):174-81. PubMed ID: 6298424
[TBL] [Abstract][Full Text] [Related]
72. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
73. Flavonoids are selective cyclic GMP phosphodiesterase inhibitors.
Ruckstuhl M; Beretz A; Anton R; Landry Y
Biochem Pharmacol; 1979; 28(4):535-8. PubMed ID: 218594
[No Abstract] [Full Text] [Related]
74. Effects of polyphloretin phosphate (PPP) and quinterenol of cyclic nucleotide phosphodiesterase activities.
Curtis-Prior PB; Chan YH
Pharmacol Res Commun; 1981 Apr; 13(4):331-7. PubMed ID: 6270700
[No Abstract] [Full Text] [Related]
75. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
[TBL] [Abstract][Full Text] [Related]
76. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation.
Rybalkin SD; Bornfeldt KE
Thromb Haemost; 1999 Aug; 82(2):424-34. PubMed ID: 10605733
[No Abstract] [Full Text] [Related]
77. Guanosine 3':5'-cyclic monophosphate: a possible intracellular mediator of mitogenic influences in lymphocytes.
Hadden JW; Hadden EM; Haddox MK; Goldberg ND
Proc Natl Acad Sci U S A; 1972 Oct; 69(10):3024-7. PubMed ID: 4342973
[TBL] [Abstract][Full Text] [Related]
78. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro.
Ruppert D; Weithmann KU
Life Sci; 1982 Nov; 31(19):2037-43. PubMed ID: 6294426
[TBL] [Abstract][Full Text] [Related]
79. Activation of murine lymphocytes by cyclic guanosine 3',5'-monophosphate: specificity and role in mitogen activity.
Derubertis FR; Zenser T
Biochim Biophys Acta; 1976 Mar; 428(1):91-103. PubMed ID: 4115
[TBL] [Abstract][Full Text] [Related]
80. Effects of CuCl2 on the hydrolysis of cyclic GMP and cyclic AMP by the activator-dependent cyclic nucleotide phosphodiesterase from bovine heart.
Donnelly TE
Biochim Biophys Acta; 1978 Oct; 543(3):273-82. PubMed ID: 213129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
